The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: Additive blood glucose lowering effect and decreased hypoglycaemia

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 15, Issue 3, 2002, Pages 143-151

  Rosak, Christoph ^a   Haupt, E ^a   Walter, T ^a   Werner, J ^a  

^a KRANKENHAUS SACHSENHAUSEN   (Germany)

Author keywords

Acarbose; Blood glucose; Glibenclamide; Hypoglycaemia; Insulin

Indexed keywords

ACARBOSE; AMPHETAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; CARBOHYDRATE; GLIBENCLAMIDE; GLUCOCORTICOID; GLUCOSE; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA; THIAZIDE DIURETIC AGENT; ANTIDIABETIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FOOD; KINETICS;

ACARBOSE; ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOOD; GLYBURIDE; HUMAN; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; MALE; PLACEBOS; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 0036316750     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The Bedford Survey: Ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycemic controls and risk indices for coronary heart disease in borderline diabetics
2. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry - Honolulu Heart Program
3. Relationship of post-load plasma glucose to mortality with 19-yr follow up
4. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status
5. The postprandial state and the risk of atherosclerosis
6. Asymptomatic hyperglycemia and early atherosclerotic changes
7. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men - The Rancho Bernardo Study
8. The importance of hyperglycemia in the non-fasting state to the development of cardiovascular disease
9. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose
10. Glucose tolerance and mortality in the DECODE study: Comparison of the WHO and the ADA diagnostic criteria
11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33)
12. The effects of alpha-glucosidase inhibitor BAY G 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin and triglyceride levels in man
13. Pharmacology of amylase- And glucosidase inhibitors
14. + channel in insulin secreting cells
15. Alpha-glucosidase inhibitors as agents in the treatment of diabetes
16. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients
17. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide and tolbutamide-plus-acarbose in NIDDM
18. Multicentric clinical trial to assess efficacy and tolerability of acarbose in comparison to glibenclamide and placebo
19. A randomized double-blind trial of acarbose in Type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44)
20. The efficacy of acarbose in the treatment of patients with NIDDM
21. Acarbose in ambulatory treatment of NIDDM associated to imminent sulfonylurea failure: A randomized-multicentric trial in primary health care
22. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulfonylureas: A randomized, placebo-controlled study
23. Wirksamkeit und Verträglichkeit von einschleichend dosierter Acarbose bei Patienten mit Typ-II-Diabetes unter Sulfonylharnstofftherapie
24. The comparison of several dose levels with a zero dose control